The estimated Net Worth of Krishnan Nandabalan is at least $14.8 millió dollars as of 6 April 2023. Dr Nandabalan owns over 60,000 units of BioXcel Therapeutics Inc stock worth over $33,000 and over the last 6 years he sold BTAI stock worth over $14,590,298. In addition, he makes $150,000 as Chief Digital Officer ?& Director at BioXcel Therapeutics Inc.
Sign up
Dr Nandabalan BTAI stock SEC Form 4 insiders trading
Dr has made over 5 trades of the BioXcel Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 60,000 units of BTAI stock worth $24,600 on 6 April 2023.
The largest trade he's ever made was selling 473,250 units of BioXcel Therapeutics Inc stock on 25 June 2021 worth over $14,590,298. On average, Dr trades about 81,781 units every 199 days since 2018. As of 6 April 2023 he still owns at least 60,000 units of BioXcel Therapeutics Inc stock.
You can see the complete history of Dr Nandabalan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Krishnan Nandabalan biography
Dr. Krishnan Nandabalan is the Chief Digital Officer ?& Director at BioXcel Therapeutics Inc.
What is the salary of Dr Nandabalan?
As the Chief Digital Officer ?& Director of BioXcel Therapeutics Inc, the total compensation of Dr Nandabalan at BioXcel Therapeutics Inc is $150,000. There are 7 executives at BioXcel Therapeutics Inc getting paid more, with Vimal Mehta having the highest compensation of $1,968,930.
How old is Dr Nandabalan?
Dr Nandabalan is 58, he's been the Chief Digital Officer ?& Director of BioXcel Therapeutics Inc since . There are 7 older and 7 younger executives at BioXcel Therapeutics Inc. The oldest executive at BioXcel Therapeutics Inc is Dr. Frank D. Yocca Ph.D., 65, who is the Sr. VP & Chief Scientific Officer.
What's Dr Nandabalan's mailing address?
Krishnan's mailing address filed with the SEC is C/O BIOXCEL THERAPEUTICS, INC.,, 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511.
Insiders trading at BioXcel Therapeutics Inc
Over the last 7 years, insiders at BioXcel Therapeutics Inc have traded over $63,244,788 worth of BioXcel Therapeutics Inc stock and bought 45,656 units worth $321,105 . The most active insiders traders include Vimal Bio Xcel Holdings, In..., Vimal Mehta és Krishnan Nandabalan. On average, BioXcel Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $29,814. The most recent stock trade was executed by Matthew T. Wiley on 15 June 2024, trading 750 units of BTAI stock currently worth $413.
What does BioXcel Therapeutics Inc do?
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
What does BioXcel Therapeutics Inc's logo look like?
Complete history of Dr Nandabalan stock trades at BioXcel Therapeutics Inc
BioXcel Therapeutics Inc executives and stock owners
BioXcel Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Vimal Mehta,
President, Chief Executive Officer, Co-Founder, Secretary, Director -
Dr. Vimal D. Mehta Ph.D.,
Founder, CEO, Pres, & Director -
Frank Yocca,
Chief Scientific Officer -
Vincent O'Neill,
Chief Medical Officer -
Richard Steinhart,
Chief Financial Officer -
Peter Mueller,
Independent Chairman of the Board -
Sandeep Laumas,
Independent Director -
Dr. Krishnan Nandabalan,
Chief Digital Officer ?& Director -
Michal Votruba,
Independent Director -
John Graziano,
IR Contact Officer -
Reina Benabou,
Senior Vice President, Chief Development Officer -
Will Kane,
Executive Vice President, Chief Commercial Officer -
Krishnan Nandabalan,
Co-Founder, Director, Chief Digital Officer -
Matthew Wiley,
Sr. VP & Chief Commercial Officer -
Dr. Iris Francesconi Ph.D.,
Sr. VP of Marketing, Market Research & Commercial Assessments -
Dr. Frank D. Yocca Ph.D.,
Sr. VP & Chief Scientific Officer -
Richard I. Steinhart MBA,
Sr. VP & CFO -
Dr. Reina Benabou M.D., Ph.D.,
Sr. VP & Chief Devel. Officer -
William P. Kane Jr.,
Exec. VP & Chief Commercial Officer -
Dr. David C. Hanley,
Head of Global Pharmaceutical Devel. and Operations & VP -
Dr. Cedric Burg,
VP and Head of Global Clinical Operations & Project Management -
Javier Rodriguez,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Mary Coleman,
VP of Investment Relations -
Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P.,
Sr. VP & Chief Medical Officer -
Llc Bio Xcel,
10% owner -
Holdings, Inc. Bio Xcel,
10% owner -
Matthew T. Wiley,
Chief Commercial Officer -
Michael Patrick Miller,
Director -
June Bray,
Director -
Vimal Bio Xcel Holdings, In...,
CEO and President